{
    "clinical_study": {
        "@rank": "164678", 
        "arm_group": [
            {
                "arm_group_label": "Low Dose", 
                "arm_group_type": "Experimental", 
                "description": "One or two doses of replication incompetent adenovirus given in a tablet"
            }, 
            {
                "arm_group_label": "Placebo Tablet", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Tablets of the same size and shape as the experimental"
            }, 
            {
                "arm_group_label": "Medium Dose", 
                "arm_group_type": "Experimental", 
                "description": "One or two doses of replication incompetent adenovirus given in a tablet"
            }, 
            {
                "arm_group_label": "High Dose", 
                "arm_group_type": "Experimental", 
                "description": "One dose of replication incompetent adenovirus given in a tablet"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to demonstrate the safety and immunogenicity of an oral vaccine\n      to prevent seasonal influenza.  Volunteers will receive placebo as part of the study."
        }, 
        "brief_title": "Safety Study of an Oral Vaccine to Prevent Seasonal Influenza", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Season Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  In good health as established by medical history, physical examination, and\n             laboratory testing at the time of enrollment.\n\n        Exclusion Criteria:\n\n          -  Positive for H1 influenza by HAI.\n\n          -  Has had an influenza vaccine in the past 2 years.\n\n          -  Current history of chronic alcohol consumption and/or illicit and/or recreational\n             drug use.\n\n          -  History of any confirmed or suspected immunodeficient or immunosuppressive condition\n\n          -  Positive serology for HIV, HCV, or HBV\n\n          -  Previous serious reactions to vaccination such as anaphylaxis, respiratory problems,\n             hives, or abdominal pain.\n\n          -  History of irritable bowel disease or other inflammatory digestive or\n             gastrointestinal conditions that could affect the intended distribution of the\n             vaccine targeting the mucosa of the small intestine\n\n          -  Use of proton pump inhibitors(Nexium, Prilosec).\n\n          -  Stool sample with occult blood at baseline exam"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "49 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01688297", 
            "org_study_id": "VXA02-001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Low Dose", 
                    "Medium Dose", 
                    "High Dose"
                ], 
                "intervention_name": "One or two doses of replication incompetent adenovirus given in a tablet", 
                "intervention_type": "Biological", 
                "other_name": "Ad-HA-dsRNA"
            }, 
            {
                "arm_group_label": "Placebo Tablet", 
                "intervention_name": "Placebo Tablet", 
                "intervention_type": "Biological", 
                "other_name": "Placebo Control"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Influenza", 
            "H1N1", 
            "flu", 
            "seasonal"
        ], 
        "lastchanged_date": "January 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cypress", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90630"
                }, 
                "name": "WCCT"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized Phase 1 Double-Blinded Placebo Controlled Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Seasonal Influenza A Vaccine and dsRNA Adjuvant Administered Orally to Healthy Volunteers Age 18-49 Years", 
        "overall_contact": {
            "email": "Erin.Foster@wcct.com", 
            "last_name": "Erin Foster"
        }, 
        "overall_official": [
            {
                "affiliation": "Vaxart, Inc.", 
                "last_name": "David Liebowitz, MD, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "WCCT", 
                "last_name": "Apinya Vutikullird, DO", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Frequency or severity of vaccine related events as measured through reported AEs.", 
            "safety_issue": "Yes", 
            "time_frame": "up to 1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01688297"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Magnitude of humoral immune response to influenza as measured by functional assays", 
                "safety_issue": "No", 
                "time_frame": "up to 1 year"
            }, 
            {
                "measure": "Magnitude of cellular immune responses to influenza as measured by functional assays", 
                "safety_issue": "No", 
                "time_frame": "up to 1 year"
            }
        ], 
        "source": "Vaxart", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Vaxart", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}